FDA’s 25-Year Sunscreen Stall Exposed

The real story is not just that the Food and Drug Administration approved a new sunscreen ingredient. It is that Americans waited more than 25 years for a filter many other countries had long already used.

Story Snapshot

Bemotrizinol is now approved for United States sunscreen products.^[6]^[7]
The ingredient protects against both UVA and UVB rays.^[6]^[1]
The Food and Drug Administration found it has low skin absorption and rarely causes irritation.^[6]^[1]
The long delay reflects how slowly the United States adds new sunscreen actives.^[9]^[10]

Why This Approval Matters

Bemotrizinol gives American sunscreen makers a broader tool. The Food and Drug Administration says it protects against both ultraviolet A and B rays, has low absorption through the skin, and rarely causes skin irritation.^[6] That matters because consumers do not just want sun protection. They want formulas that feel better, hold up longer, and do not leave the chalky look people still complain about with some mineral products.^[1]^[4]

That practical appeal is part of why the approval drew so much attention. CBS News reported that the ingredient has been used in Europe and other parts of the world for years, and that it fills an important niche in the United States market.^[1] ABC News said it is more stable in sunlight than some other ultraviolet filters, which means it breaks down less easily.^[5] For a daily product, that stability is not a small detail. It is the difference between a sunscreen people actually wear and one they leave on the shelf.

Why It Took So Long

The slow pace comes from the way the United States regulates sunscreen. The Food and Drug Administration treats sunscreen active ingredients as over-the-counter drug ingredients, so companies must clear a safety-and-effectiveness standard before sale.^[6]^[9] That process is stricter than the lighter paths used in some other markets. The agency’s own proposal says bemotrizinol would be added only after review of data showing protection, low absorption, and rare irritation.^[6]

That does not erase the frustration many people feel. The ingredient was already approved in Europe in 2000, according to TIME and other reporting.^[3]^[7] So the gap was not about whether the ingredient existed or had a record somewhere else. It was about whether United States regulators had enough evidence, in their own system, to call it generally recognized as safe and effective.^[6]^[7] That distinction sounds bureaucratic, but it is the whole game.

The Bigger Problem Behind the Headline

Bemotrizinol is important because it exposes a bigger bottleneck. FDA has been criticized for moving slowly on sunscreen innovation for years, while countries in Europe and Asia have had access to newer filters for much longer.^[3]^[10] Congress tried to speed this up through the 2020 CARES Act and the streamlined over-the-counter monograph order process, which was meant to modernize sunscreen review.^[9]^[10] Bemotrizinol is the kind of case that shows why that reform mattered.

The FDA approved bemotrizinol, the first new active ingredient for over-the-counter sunscreens in more than 20 years.

This chemical filter offers broad-spectrum protection against both UVA and UVB rays at concentrations up to 6 percent. It shows low skin absorption and rarely… pic.twitter.com/0FWsa11lUM

— The Epoch Times (@EpochTimes) June 10, 2026

At the same time, the approval also supports the cautious side of the argument. The Food and Drug Administration did not wave this through on hype. It reviewed submitted data and concluded the ingredient is generally recognized as safe and effective for adults and children 6 months and older.^[6]^[7] That is the right standard for an ingredient meant for mass use, especially when it will be spread across the skin of millions of people, including children.

What Consumers Should Expect Next

The approval does not mean every store shelf changes overnight. CBS News reported that DSM Nutritional Products will likely bring the ingredient to market first, and other manufacturers can follow after the exclusivity period ends.^[1] That means better sunscreens may arrive in stages, not all at once. Consumers may first notice formulas that spread more smoothly, feel less greasy, and offer better broad-spectrum coverage without the familiar tradeoffs of older products.

The broader lesson is simple. When regulation moves too slowly, the public loses time with better tools. When it moves recklessly, people pay for mistakes. In this case, the Food and Drug Administration appears to have landed on the sober middle ground: late, but defensible. For ordinary families trying to protect skin every summer, that may matter more than the fight over who deserves the credit.